Prognostic impact of KRAS G12C mutation in patients with NSCLC: results from the European Thoracic Oncology Platform Lungscape project
Introduction - KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inh...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
26 February 2021
|
| In: |
Journal of thoracic oncology
Year: 2021, Jahrgang: 16, Heft: 6, Pages: 990-1002 |
| ISSN: | 1556-1380 |
| DOI: | 10.1016/j.jtho.2021.02.016 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jtho.2021.02.016 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1556086421017342 
|
| Verfasserangaben: | Stephen P. Finn, Alfredo Addeo, Urania Dafni, Erik Thunnissen, Lukas Bubendorf, Line Bille Madsen, Wojciech Biernat, Eric Verbeken, Javier Hernandez-Losa, Antonio Marchetti, Richard Cheney, Arne Warth, Ernst-Jan M. Speel, Anne Marie Quinn, Kim Monkhorst, Eloisa Jantus-Lewintre, Verena Tischler, Nesa Marti, Georgia Dimopoulou, Miguel A. Molina-Vila, Roswitha Kammler, Keith M. Kerr, Solange Peters, Rolf A. Stahel on behalf of the European Thoracic Oncology Platform Lungscape Investigators |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1790041945 | ||
| 003 | DE-627 | ||
| 005 | 20240415193331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220218s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtho.2021.02.016 |2 doi | |
| 035 | |a (DE-627)1790041945 | ||
| 035 | |a (DE-599)KXP1790041945 | ||
| 035 | |a (OCoLC)1341441861 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Finn, Stephen P. |e VerfasserIn |0 (DE-588)1252085338 |0 (DE-627)1790044413 |4 aut | |
| 245 | 1 | 0 | |a Prognostic impact of KRAS G12C mutation in patients with NSCLC |b results from the European Thoracic Oncology Platform Lungscape project |c Stephen P. Finn, Alfredo Addeo, Urania Dafni, Erik Thunnissen, Lukas Bubendorf, Line Bille Madsen, Wojciech Biernat, Eric Verbeken, Javier Hernandez-Losa, Antonio Marchetti, Richard Cheney, Arne Warth, Ernst-Jan M. Speel, Anne Marie Quinn, Kim Monkhorst, Eloisa Jantus-Lewintre, Verena Tischler, Nesa Marti, Georgia Dimopoulou, Miguel A. Molina-Vila, Roswitha Kammler, Keith M. Kerr, Solange Peters, Rolf A. Stahel on behalf of the European Thoracic Oncology Platform Lungscape Investigators |
| 246 | 3 | 3 | |a Prognostic impact of KRAS G twelve C mutation in patients with NSCLC |
| 264 | 1 | |c 26 February 2021 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.02.2022 | ||
| 520 | |a Introduction - KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). - Methods - KRAS mutations were evaluated in formalin-fixed, paraffin-embedded tissue sections by a microfluidic-based multiplex polymerase chain reaction platform as a component of the previously published European Thoracic Oncology Platform Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I to III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathologic characteristics, molecular profiles, and postoperative patient outcome (overall survival, relapse-free survival, time-to-relapse) were explored. - Results - KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 [49%]) with I or II or III stage respective distribution of 53% or 24% or 22% and median follow-up of 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0% (95% confidence interval (CI): 35.0% to 41.0%), with Kr_G12C mutation representing 17.0% (95% CI: 14.7% to 19.4%). In the "histologic-subtype" cohort, Kr_G12C prevalence was 10.5% (95% CI: 9.2% to 11.9%). When adjusting for clinicopathologic characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or nonexistence of KRAS mutation was identified in the adenocarcinoma cohort alone and in the "histologic-subtype" cohort. For overall survival in adenocarcinomas, hazard ratio (HR)G12C versus other KRAS is equal to 1.39 (95% CI: 1.03 to 1.89, p = 0.031) and HRG12C versus no KRAS is equal to 1.32 (95% CI: 1.03 to 1.69, p = 0.028) (both also significant in the "histologic-subtype" cohort). For time-to-relapse, HRG12C versus other KRAS is equal to 1.41 (95% CI: 1.03 to 1.92, p = 0.030). In addition, among all patients, for relapse-free survival, HRG12C versus no KRAS is equal to 1.27 (95% CI: 1.04 to 1.54, p = 0.017). - Conclusions - In this large, clinically annotated stage I to III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathologic characteristics) among adenocarcinomas and in unselected NSCLCs. | ||
| 650 | 4 | |a Kr_G12C | |
| 650 | 4 | |a KRAS | |
| 650 | 4 | |a Multiplex PCR platform | |
| 650 | 4 | |a NSCLC | |
| 700 | 1 | |a Addeo, Alfredo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dafni, Urania |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thunnissen, Erik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bubendorf, Lukas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Madsen, Line Bille |e VerfasserIn |4 aut | |
| 700 | 1 | |a Biernat, Wojciech |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verbeken, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hernandez-Losa, Javier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marchetti, Antonio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cheney, Richard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Warth, Arne |d 1979- |e VerfasserIn |0 (DE-588)132646145 |0 (DE-627)524716927 |0 (DE-576)260019755 |4 aut | |
| 700 | 1 | |a Speel, Ernst-Jan M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Quinn, Anne Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Monkhorst, Kim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jantus-Lewintre, Eloisa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tischler, Verena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marti, Nesa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dimopoulou, Georgia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Molina-Vila, Miguel A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kammler, Roswitha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kerr, Keith M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Peters, Solange |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stahel, Rolf A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thoracic oncology |d Amsterdam : Elsevier, 2006 |g 16(2021), 6 vom: Juni, Seite 990-1002 |h Online-Ressource |w (DE-627)508331986 |w (DE-600)2223437-8 |w (DE-576)336961553 |x 1556-1380 |7 nnas |a Prognostic impact of KRAS G12C mutation in patients with NSCLC results from the European Thoracic Oncology Platform Lungscape project |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:6 |g month:06 |g pages:990-1002 |g extent:13 |a Prognostic impact of KRAS G12C mutation in patients with NSCLC results from the European Thoracic Oncology Platform Lungscape project |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jtho.2021.02.016 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1556086421017342 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220218 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 132646145 |a Warth, Arne |m 132646145:Warth, Arne |d 50000 |e 50000PW132646145 |k 0/50000/ |p 12 | ||
| 999 | |a KXP-PPN1790041945 |e 4063070999 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Prognostic impact of KRAS G12C mutation in patients with NSCLC","subtitle":"results from the European Thoracic Oncology Platform Lungscape project","title":"Prognostic impact of KRAS G12C mutation in patients with NSCLC"}],"person":[{"role":"aut","display":"Finn, Stephen P.","roleDisplay":"VerfasserIn","given":"Stephen P.","family":"Finn"},{"roleDisplay":"VerfasserIn","display":"Addeo, Alfredo","role":"aut","family":"Addeo","given":"Alfredo"},{"roleDisplay":"VerfasserIn","display":"Dafni, Urania","role":"aut","family":"Dafni","given":"Urania"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Thunnissen, Erik","given":"Erik","family":"Thunnissen"},{"given":"Lukas","family":"Bubendorf","role":"aut","display":"Bubendorf, Lukas","roleDisplay":"VerfasserIn"},{"given":"Line Bille","family":"Madsen","role":"aut","roleDisplay":"VerfasserIn","display":"Madsen, Line Bille"},{"roleDisplay":"VerfasserIn","display":"Biernat, Wojciech","role":"aut","family":"Biernat","given":"Wojciech"},{"given":"Eric","family":"Verbeken","role":"aut","display":"Verbeken, Eric","roleDisplay":"VerfasserIn"},{"given":"Javier","family":"Hernandez-Losa","role":"aut","roleDisplay":"VerfasserIn","display":"Hernandez-Losa, Javier"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Marchetti, Antonio","given":"Antonio","family":"Marchetti"},{"given":"Richard","family":"Cheney","role":"aut","roleDisplay":"VerfasserIn","display":"Cheney, Richard"},{"given":"Arne","family":"Warth","role":"aut","display":"Warth, Arne","roleDisplay":"VerfasserIn"},{"family":"Speel","given":"Ernst-Jan M.","roleDisplay":"VerfasserIn","display":"Speel, Ernst-Jan M.","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Quinn, Anne Marie","role":"aut","family":"Quinn","given":"Anne Marie"},{"family":"Monkhorst","given":"Kim","display":"Monkhorst, Kim","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Jantus-Lewintre, Eloisa","roleDisplay":"VerfasserIn","role":"aut","family":"Jantus-Lewintre","given":"Eloisa"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Tischler, Verena","given":"Verena","family":"Tischler"},{"display":"Marti, Nesa","roleDisplay":"VerfasserIn","role":"aut","family":"Marti","given":"Nesa"},{"family":"Dimopoulou","given":"Georgia","roleDisplay":"VerfasserIn","display":"Dimopoulou, Georgia","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Molina-Vila, Miguel A.","given":"Miguel A.","family":"Molina-Vila"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Kammler, Roswitha","given":"Roswitha","family":"Kammler"},{"display":"Kerr, Keith M.","roleDisplay":"VerfasserIn","role":"aut","family":"Kerr","given":"Keith M."},{"family":"Peters","given":"Solange","display":"Peters, Solange","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Stahel, Rolf A.","role":"aut","family":"Stahel","given":"Rolf A."}],"titleAlt":[{"title":"Prognostic impact of KRAS G twelve C mutation in patients with NSCLC"}],"language":["eng"],"recId":"1790041945","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 18.02.2022"],"id":{"eki":["1790041945"],"doi":["10.1016/j.jtho.2021.02.016"]},"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"26 February 2021"}],"name":{"displayForm":["Stephen P. Finn, Alfredo Addeo, Urania Dafni, Erik Thunnissen, Lukas Bubendorf, Line Bille Madsen, Wojciech Biernat, Eric Verbeken, Javier Hernandez-Losa, Antonio Marchetti, Richard Cheney, Arne Warth, Ernst-Jan M. Speel, Anne Marie Quinn, Kim Monkhorst, Eloisa Jantus-Lewintre, Verena Tischler, Nesa Marti, Georgia Dimopoulou, Miguel A. Molina-Vila, Roswitha Kammler, Keith M. Kerr, Solange Peters, Rolf A. Stahel on behalf of the European Thoracic Oncology Platform Lungscape Investigators"]},"relHost":[{"id":{"zdb":["2223437-8"],"eki":["508331986"],"issn":["1556-1380"]},"origin":[{"dateIssuedDisp":"2006-","dateIssuedKey":"2006","publisher":"Elsevier ; Lippincott Williams & Wilkins","publisherPlace":"Amsterdam ; Philadelphia, Pa."}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Journal of thoracic oncology","subtitle":"JTO ; official publication of the International Association for the Study of Lung Cancer","title_sort":"Journal of thoracic oncology"}],"part":{"volume":"16","text":"16(2021), 6 vom: Juni, Seite 990-1002","extent":"13","year":"2021","issue":"6","pages":"990-1002"},"titleAlt":[{"title":"JTO"}],"pubHistory":["1.2006 -"],"recId":"508331986","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Prognostic impact of KRAS G12C mutation in patients with NSCLC results from the European Thoracic Oncology Platform Lungscape projectJournal of thoracic oncology"}],"physDesc":[{"extent":"13 S."}]} | ||
| SRT | |a FINNSTEPHEPROGNOSTIC2620 | ||